- Achieved estimated third quarter total revenue of approximately $3.7 million, including estimated product revenue of approximately $2.6 million, representing decreases of 50% and 40% respectively, compared to the prior year period, driven by lower sales of COVID-19 tests and reduced BARDA revenue offset by increased sepsis test sales.
- Achieved estimated sepsis and related revenue (non-COVID product revenue) of approximately $2.3 million, representing a record number for a single quarter and an increase of 24% compared to the prior year period.
- Executed contracts for 11 T2Dx® Instruments during the third quarter, including 3 in the U.S. and 8 outside the U.S., compared to 8 total instruments in the prior year period.
U.S. Producer Price Index Might Rise By This Much In July, Here Are The Major Macro Issues For Thursday
U.S. stocks closed sharply higher on Wednesday following the release of inflation data for July. Shares of Walt Disney Co (NYSE: DIS) jumped around 6.9% in after-hours trading on Wednesday after the company reported better-than-expected Q3 results.
